World's Best Scientists 2026 revealed!
Cornelis J. A. Punt

Cornelis J. A. Punt

D-Index & Metrics

Medicine

D-Index
98
Citations
46106
World Ranking
8790
National Ranking
345

Cornelis J. A. Punt publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Cornelis J. A. Punt sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 418 publications — 42nd percentile

42% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Cornelis J. A. Punt D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Cornelis J. A. Punt sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Cornelis J. A. Punt is affiliated with the University of Amsterdam in the Netherlands and has a significant body of research within the field of Medicine, with a primary focus on Oncology. Their work encompasses a range of subfields including Oncology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine, Surgery, and Hepatology. Their research concentrates mainly on colorectal cancer, genetic factors influencing colorectal cancer, hepatocellular carcinoma treatment and prognosis, gastric cancer management, cancer genomics and diagnostics, colorectal cancer surgical treatments, and the application of radiomics and machine learning in medical imaging.

They have authored multiple papers published in various notable journals. Some recent publications include:

  • Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer, 2020, New England Journal of Medicine
  • Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial, 2020, Journal of Clinical Oncology
  • Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study, 2022, The Lancet Oncology
  • Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial, 2021, Journal of Clinical Oncology
  • Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial, 2021, The Lancet Oncology

The scientist has collaborated frequently with several co-authors throughout their career, including Miriam Koopman, Rutger-Jan Swijnenburg, Geraldine R. Vink, Karen Bolhuis, and Geert Kazemier. Their collaborative work is often published in widely recognized venues, with the most frequent publication outlets being:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Cancer Research
  • HPB
  • European Journal of Cancer

Best Publications

  • Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial

    Joel Shapiro;J Jan B van Lanschot;Maarten C C M Hulshof;Pieter van Hagen

  • Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

    Thierry André;Kai-Keen Shiu;Tae Won Kim;Benny Vittrup Jensen

  • Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

    David Cunningham;Seppo Pyrhönen;Roger D James;Cornelis J A Punt

  • Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

    Marc Peeters;Timothy Jay Price;Andrés Cervantes;Alberto F. Sobrero

  • Direct detection of early-stage cancers using circulating tumor DNA

    Jillian Phallen;Mark Sausen;Vilmos Adleff;Alessandro Leal

  • Genome-wide cell-free DNA fragmentation in patients with cancer

    Stephen Cristiano;Alessandro Leal;Jillian Phallen;Jacob Fiksel

  • Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy

    I Jolanda M de Vries;W Joost Lesterhuis;Jelle O Barentsz;Pauline Verdijk

  • Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

    Antoni Ribas;Richard Kefford;Margaret A. Marshall;Cornelis J.A. Punt

  • Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.

    Miriam Koopman;Ninja F. Antonini;Joep Douma;Jaap Wals

  • Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial

    Eva Versteijne;Mustafa Suker;Karin Groothuis;Janine M Akkermans-Vogelaar

  • A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.

    Giuseppe Giaccone;Cornelis J. A. Punt;Yoshitaka Ando;Rita Ruijter

  • Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

    Sabine Venderbosch;Iris D Nagtegaal;Timothy S Maughan;Christopher G Smith

  • Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

    Jan Franko;Qian Shi;Jeffrey P Meyers;Timothy S Maughan

  • Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state

    I. Jolanda M. de Vries;Daniëlle J. E. B. Krooshoop;Nicole M. Scharenborg;W. Joost Lesterhuis

  • BRAF mutation in metastatic colorectal cancer.

    Jolien Tol;Iris D Nagtegaal;Cornelis J A Punt

  • Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial

    Theo Ruers;Frits Van Coevorden;Cornelis J. A. Punt;Jean-Pierre E. N. Pierie

  • Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.

    S.J. Cohen;C.J.A. Punt;N. Iannotti;B.H. Saidman

  • From tumour heterogeneity to advances in precision treatment of colorectal cancer

    Cornelis J. A. Punt;Miriam Koopman;Louis Vermeulen

  • Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

    Lieke H. J. Simkens;Harm van Tinteren;Anne May;Albert J. ten Tije

  • Cancer immunotherapy – revisited

    Willem Lesterhuis;J.B.A.G. Haanen;C.J.A. Punt

Frequent Co-Authors

Carl G. Figdor
Carl G. Figdor Radboud University
I. Jolanda M. de Vries
I. Jolanda M. de Vries Radboud University
Iris D. Nagtegaal
Iris D. Nagtegaal Radboud University
Gosse J. Adema
Gosse J. Adema Radboud University
Gerty Schreibelt
Gerty Schreibelt Radboud University
Arend Heerschap
Arend Heerschap Radboud University
Wim J.G. Oyen
Wim J.G. Oyen Humanitas University
Pieter J. Tanis
Pieter J. Tanis University of Amsterdam
Alfredo Falcone
Alfredo Falcone University of Pisa

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students exploring options in healthcare beyond traditional medical school, online degrees provide flexible, accelerated ways to launch or advance a career. Whether you’re aiming to upskill as a nurse or enter the field quickly, there are a variety of programs available.

Many registered nurses consider rn to bsn programs to enhance their credentials and open doors to higher positions. For those interested in leadership or advanced practice roles, finding the shortest dnp program online can minimize time away from work while advancing expertise in clinical or administrative areas.

If you need flexibility, you might consider online dnp programs without clinicals, which can make it easier to balance studies with job or family responsibilities. For those wishing to start their healthcare careers sooner, a 9 month lpn program offers a fast-track route into practical nursing.

These diverse online pathways make healthcare education more accessible, supporting professionals at every stage of their journey.

Best Scientists Citing Cornelis J. A. Punt

Trending Scientists

Recently Published Articles